一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:T lymphocyte cell: A pivotal player in lung cancer.
T lymphocyte cell: A pivotal player in lung cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肺癌是全球癌症相关死亡的主要原因,缺乏有效疗法。近年来,对免疫系统抗肿瘤活性认识的不断积累的证据表明,免疫治疗是肺癌治疗中强有力的替代方案之一。T细胞是细胞免疫治疗的核心,对肺癌的肿瘤发生和治疗至关重要。基于表面分子和功能点的不同表达,T细胞可细分为调节性T细胞、辅助性T细胞、细胞毒性T淋巴细胞以及其他非常规T细胞,包括γδ T细胞、自然杀伤T细胞和黏膜相关恒定T细胞。对T细胞功能机制理解的进展将促成大量关于发现和开发新治疗策略的临床试验。因此,我们总结了T细胞在肺癌肿瘤发生、进展、转移和预后中的生物学功能及调控。此外,我们讨论了当前技术的进展以及针对肺癌的T细胞导向治疗靶点的潜力。
Lung cancer is responsible for the leading cause of cancer-related death worldwide, which lacks effective therapies. In recent years, accumulating evidence on the understanding of the antitumor activity of the immune system has demonstrated that immunotherapy is one of the powerful alternatives in lung cancer therapy. T cells are the core of cellular immunotherapy, which are critical for tumorigenesis and the treatment of lung cancer.
Based on the different expressions of surface molecules and functional points, T cells can be subdivided into regulatory T cells, T helper cells, cytotoxic T lymphocytes, and other unconventional T cells, including γδ T cells, nature killer T cells and mucosal-associated invariant T cells. Advances in our understanding of T cells' functional mechanism will lead to a number of clinical trials on the discovery and development of new treatment strategies.
Thus, we summarize the biological functions and regulations of T cells on tumorigenesis, progression, metastasis, and prognosis in lung cancer.
Furthermore, we discuss the current advancements of technologies and potentials of T-cell-oriented therapeutic targets for lung cancer.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。